219 related articles for article (PubMed ID: 30153096)
1. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of essential thrombocythemia].
Alvarez-Larrán A; Cervantes F; Besses C
Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
10. Essential thrombocythemia.
Brière JB
Orphanet J Rare Dis; 2007 Jan; 2():3. PubMed ID: 17210076
[TBL] [Abstract][Full Text] [Related]
11. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Alvarez-Larrán A; Pereira A; Arellano-Rodrigo E; Hernández-Boluda JC; Cervantes F; Besses C
Br J Haematol; 2013 Jun; 161(6):865-71. PubMed ID: 23577924
[TBL] [Abstract][Full Text] [Related]
12. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
13. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Tefferi A; Szuber N; Pardanani A; Hanson CA; Vannucchi AM; Barbui T; Gangat N
Am J Hematol; 2021 Jun; 96(6):E182-E184. PubMed ID: 33617676
[No Abstract] [Full Text] [Related]
14. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
15. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
16. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
17. Pharmacotherapy of essential thrombocythemia.
Gangat N; Tefferi A
Expert Opin Pharmacother; 2008 Jul; 9(10):1679-85. PubMed ID: 18570601
[TBL] [Abstract][Full Text] [Related]
18. [Primary thrombocythemia: diagnosis and therapy].
Petrides PE
Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
Inoue S; Okiyama N; Okune M; Shiraki N; Kessoku R; Fujimoto M
J Dermatol; 2017 Jan; 44(1):84-87. PubMed ID: 27570091
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
